Cardiff Oncology to Participate in Three Upcoming Investor Conferences

SAN DIEGO, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will participate in three upcoming investor conferences in March 2026.  

TD Cowen 46th Annual Health Care Conference
Date: 03/04/26

Barclays 28th Annual Global Healthcare Conference
Date: 03/10/26

Leerink Partners Global Healthcare Conference 2026
Date: 03/11/26

Interested parties can register for and access the live webcast for the conferences by visiting the “Events” section of the Cardiff Oncology website. The webcast replay will be available after the conclusion of the presentation. 

About Cardiff Oncology, Inc.  
Cardiff Oncology is a clinical-stage biotechnology company advancing innovative cancer treatments focused on PLK1 inhibition, a validated oncology target with practice-changing potential. Our lead asset, onvansertib, is a highly specific, oral PLK1 inhibitor currently being evaluated in a Phase 2 trial for first-line treatment of RAS-mutated metastatic colorectal cancer (“mCRC”), addressing a large, underserved patient population with high unmet need. Onvansertib is also under investigation in other PLK1-driven cancers through ongoing investigator-initiated trials and has shown robust single agent clinical activity in hard-to-treat tumors. By targeting tumor vulnerabilities, we aim to overcome treatment resistance and deliver improved clinical outcomes for patients.

For more information, please visit https://www.cardiffoncology.com.

Investor Contact: 
Candice Masse 
Astr Partners 
[email protected]   

Media Contact:  
Amy Bonanno  
Lyra Strategic Advisory  
[email protected]